Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00845507 · ClinicalTrials.gov registry record · Phase 4
Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
A Phase 4 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 54
- Enrollment target
NCT00845507 is a Phase 4 study that has completed, run by University of Cincinnati. The registered enrollment target is 54 participants.
The verdict
NCT00845507, a Phase 4 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the safety and efficacy (how well it works) of exenatide as a treatment for weight gain associated with olanzapine in obese adults with Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder Exenatide has been approved by the FDA for the treatment of Type 2 diabetes. It has not been approved for the treatment of weight gain associated with olanzapine in obese adults with bipolar disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder
Interventions
- DRUG Placebo
- DRUG Exenatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2008-12 |
| Est. Completion | 2015-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00845507
The ClinicalTrials.gov registry entry for NCT00845507 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00845507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00845507 about?
NCT00845507 is a clinical study titled "Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults". The purpose of this research study is to test the safety and efficacy (how well it works) of exenatide as a treatment for weight gain associated with olanzapine in obese adults with Bipolar Disorder, Major Depressive Disorder, Schizophrenia or Schizoaffective Disorder Exenatide has been approved by...
What is the current status of trial NCT00845507?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 54 participants. The study started on 2008-12. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00845507?
The interventions under investigation include: Placebo (DRUG), Exenatide (DRUG).
Who is sponsoring clinical trial NCT00845507?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.